In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
In children aged 6 to
In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.
In adults with obesity (BMI ≥30 kg/m²), daily subcutaneous semaglutide significantly promoted weight loss compared to liraglutide and placebo, with gastrointestinal symptoms as the main side effect.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
